Newsroom

NIH has awarded seven contracts to companies and academic institutions to develop digital health solutions that help address the COVID-19 pandemic.

NIH announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of RADx. These tests add to initial awards made to seven companies on July 31, 2020.

The winners of National Institutes of Health’s 9th annual Design by Biomedical Undergraduate Teams (DEBUT) challenge developed simple and low-cost diagnostics and treatments for conditions such as tuberculosis, cervical cancer, birth defects, and onchocerciasis (river blindness).

The National Institutes of Health has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.

In a paper in the New England Journal of Medicine, scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.

Scientists at NIBIB have developed new image processing techniques for microscopes that can reduce post-processing time up to several thousand-fold.

NIH has announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.

A new study has begun recruiting at the National Institutes of Health in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have antibodies to the virus.